Physician profile
Michael D Sable
NPI 1891788337
$6,959.32
in general payments reported to CMS, 2019-2025
30 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $588 · 2021: $617 · 2022: $886 · 2023: $1,009 · 2024: $1,420 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Charitable Contribution: $900 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.94 |
| Charitable Contribution | $900.42 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,697.18 | 2019-2025 | Clareon, Tryptyr, Simbrinza |
| Microsurgical Technology, INC. | $900.42 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $586.97 | 2019-2024 | Veritas Vision System, Catalys System, Tecnis Iol |
| Biotissue Holdings INC. | $396.68 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $354.71 | 2019-2024 | Cequa |
| Oyster Point Pharma, INC. | $342.69 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $329.89 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayner Cataract Set 1 |
| Mallinckrodt Hospital Products INC. | $275.61 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $256.60 | 2022-2024 | Envista Mx60 Iol, Doctors Allergy Formula, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $243.12 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $178.29 | 2024-2025 | Xdemvy |
| Abbvie INC. | $172.95 | 2022-2025 | |
| Allergan, INC. | $162.14 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $149.99 | 2019-2021 | |
| Harrow Eye, LLC | $144.01 | 2024-2025 | Vevye |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $129.28 | 2019-2023 | |
| Glaukos Corporation | $98.07 | 2024-2025 | Idose, Idosetr |
| Johnson & Johnson Vision Care, INC. | $87.09 | 2024 | Veritas Vision System |
| Ocular Therapeutix, INC. | $78.70 | 2019-2023 | Dextenza |
| Rxsight INC | $77.05 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Eyevance Pharmaceuticals LLC | $63.65 | 2019-2021 | |
| Ivantis, INC | $39.19 | 2020 | |
| Amgen INC. | $37.48 | 2024 | Tepezza |
| Coherus Oncology, INC. | $29.59 | 2023 | |
| Dompe US, INC. | $28.39 | 2025 | Oxervate |
| Halozyme INC | $23.00 | 2024 | Hylenex Recombinant |
| Genentech USA, INC. | $21.98 | 2024 | Vabysmo |
| New World Medical,INC. | $19.89 | 2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Eyepoint US, INC. | $17.71 | 2019 | |
| Sight Sciences, INC. | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.